Sheng-Yu Ku
Harvard University
H-index: 19
North America-United States
Top articles of Sheng-Yu Ku
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes | Varadha Balaji Venkadakrishnan Adam G Presser Richa Singh Matthew A Booker Nicole A Traphagen | 2024/2/8 | |
Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression | Oncogene | Karina A Miller Seamus Degan Yanqing Wang Joseph Cohen Sheng Yu Ku | 2024/1/4 |
PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression | Oncogene | Karina A Miller Seamus Degan Yanqing Wang Joseph Cohen Sheng Yu Ku | 2024/1/4 |
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial | JNCI: Journal of the National Cancer Institute | Takayuki Sumiyoshi Xiaofei Wang Evan W Warner Andrea Sboner Matti Annala | 2024/1/1 |
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation | Cancer discovery | Gian Marco Franceschini Orsetta Quaini Kei Mizuno Francesco Orlando Yari Ciani | 2024/3/1 |
Abstract B017: Lineage-specific PRC2 targets and response to EZH2 inhibition in neuroendocrine prostate cancer | Cancer Research | Varadha Balaji Venkadakrishnan Richa Singh Yasutaka Yamada Kei Mizuno Adam G Presser | 2023/6/2 |
Abstract PR008: Molecular determinants of prostate cancer lineage plasticity | Cancer Research | Kristine Wadosky Sheng-Yu Ku Yanqing Wang Xiaojing Zhang Jie Wang | 2023/6/2 |
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer | Nature cancer | Martin K Bakht Yasutaka Yamada Sheng-Yu Ku Varadha Balaji Venkadakrishnan Joshua A Korsen | 2023/5 |
Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer | Science Translational Medicine | Yasutaka Yamada Varadha Balaji Venkadakrishnan Kei Mizuno Martin Bakht Sheng-Yu Ku | 2023/11/15 |
The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer | Cancer research communications | Lucie Van Emmenis Sheng-Yu Ku Kaitlyn Gayvert Jonathan R Branch Nicholas J Brady | 2023/8/3 |
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer | Scientific Reports | Fabio Quaglia Shiv Ram Krishn Khalid Sossey-Alaoui Priyanka Shailendra Rana Elzbieta Pluskota | 2022/11/7 |
DLL3-targeted T cell engager therapy (HPN328) for neuroendocrine prostate cancer | Cancer Research | Sheng-Yu Ku Yasutaka Yamada Patrick Ng Laura Sun Himisha Beltran | 2022/6/15 |
Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer | bioRxiv | Daksh Thaper Ravi Munuganti Adeleke Aguda Soojin Kim Shengyu Ku | 2022/5/5 |
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells | Proceedings of the National Academy of Sciences | Martin K Bakht John J Hayward Farsheed Shahbazi-Raz Magdalena Skubal Ryo Tamura | 2022/1/25 |
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis | NPJ Precision Oncology | Vincenza Conteduca Sheng-Yu Ku Luisa Fernandez Angel Dago-Rodriquez Jerry Lee | 2021 |
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer | Nature communications | Meixia Che Aashi Chaturvedi Sarah A Munro Samuel P Pitzen Alex Ling | 2021/11/4 |
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis | NPJ precision oncology | Vincenza Conteduca Sheng-Yu Ku Luisa Fernandez Angel Dago-Rodriquez Jerry Lee | 2021/8/12 |
Epigenetics in prostate cancer: clinical implications | Vincenza Conteduca Judy Hess Yasutaka Yamada Sheng-Yu Ku Himisha Beltran | 2021/7 | |
Activated ALK cooperates with N-Myc via Wnt/β-catenin signaling to induce neuroendocrine prostate cancer | Cancer research | Kenji Unno Zachary R Chalmers Sahithi Pamarthy Rajita Vatapalli Yara Rodriguez | 2021/4/15 |
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer | Nature communications | Sylvan C Baca David Y Takeda Ji-Heui Seo Justin Hwang Sheng Yu Ku | 2021/3/30 |
